Catalent is a leading global Contract Development and Manufacturing Organization (CDMO). The company provides a comprehensive suite of services, including formulation development, clinical and commercial manufacturing, advanced drug delivery technologies (like softgels and biologics), and packaging solutions for the pharmaceutical, biotech, and consumer health industries. Its role is crucial in accelerating and de-risking the journey of new therapies from the lab to the patient.

Why AI matters at this scale

For an enterprise of Catalent's size (over 10,000 employees) operating in the highly complex, regulated, and capital-intensive pharmaceutical sector, AI is not a luxury but a strategic necessity for maintaining competitive advantage. The sheer volume of data generated across dozens of global manufacturing sites, thousands of development projects, and a sprawling clinical supply chain presents both a challenge and an immense opportunity. Manual analysis cannot keep pace. AI offers the tools to unlock insights from this data, driving unprecedented efficiencies in a business where margins are tight, timelines are critical, and quality is non-negotiable. At this scale, even a single-digit percentage improvement in yield, speed, or asset utilization translates to tens or hundreds of millions in annual value.

Concrete AI opportunities with ROI framing

1. AI-Optimized Biologics Manufacturing: Biologics production is notoriously variable and expensive. Implementing AI for predictive process control can analyze real-time sensor data to maintain optimal conditions, forecast cell culture performance, and preemptively adjust parameters. This can increase batch success rates and yield by 5-15%, directly boosting revenue from high-value contracts and reducing costly reprocessing.

2. Generative AI for Formulation Acceleration: Developing new drug formulations is a trial-and-error process. Generative AI models can propose novel excipient combinations and delivery system designs based on target product profiles and historical data. This can cut early-stage development time by 30-50%, allowing Catalent to serve more clients faster and capture greater market share in a service-driven business.

3. Intelligent Clinical Trial Supply Management: Managing global supplies for hundreds of clinical trials is a logistical nightmare. AI-driven demand forecasting and dynamic routing can optimize inventory levels across depots, minimize drug wastage (which can be millions per trial), and ensure sites are never starved of material. This improves client satisfaction, reduces operational costs, and mitigates a major risk in clinical development.

Deployment risks specific to this size band

For a large, geographically dispersed enterprise like Catalent, AI deployment faces unique hurdles. Data Silos and Integration: Legacy systems (ERP, MES, LIMS) across acquired sites create fragmented data landscapes, making it difficult to build enterprise-wide AI models. Change Management at Scale: Rolling out AI-driven workflows requires retraining thousands of employees across different cultures and functions, risking slow adoption if not managed meticulously. Regulatory Scrutiny: Any AI tool impacting product quality or manufacturing must undergo rigorous validation for FDA and other global health authorities. A failed audit or delayed approval can halt a rollout across the entire network, amplifying the cost of missteps. Vendor Lock-in: Partnering with a single AI vendor for a critical function could create strategic vulnerability, making it essential to prioritize interoperable, modular platforms.